Shikonin is a specific PKM2 inhibitor that not only inhibits glucose uptake and lactate production in tumor cells, but also inhibits glycolysis by reducing extracellular secretion of exosomal PKM2 and enhances cisplatin sensitivity in NSCLC cells [290]. Here, PKM is linked to non-small cell lung carcinoma.